Host a clinical trial
Host a clinical trial

ACLF clinical trials

Discover our current clinical trials in the field of ACLF, targeting multiple pathways to tackle this complex syndrome.
Phase 2

UNVEIL-IT® – VS-01

This is a Phase 2 study conducted at multiple locations in the U.S. and Europe, in which participants with ACLF are randomly assigned to one of two treatment groups. In this open-label study, both participants and doctors know which treatment is being given. The goal is to determine whether a new investigational drug called VS-01, when combined with the standard of care (the recommended treatments for patients with ACLF, based on individual medical needs), can help in the treatment of patients with ACLF compared to those receiving only the standard of care.

Proof of concept

SRT-015 To be launched in 2025

SRT-015 is a targeted investigational drug that is designed to block ASK1 (Apoptosis Signal-regulating Kinase 1), a protein involved in liver damage and inflammation. This investigational drug may work in multiple ways to protect the liver, including reducing inflammation, preventing cell damage, and slowing down liver scarring. Preclinical studies have shown that SRT-015 may be a promising therapy for both acute and chronic liver conditions, including ACLF.

Proof of concept

NTZ To be launched in 2025

NTZ and its active form, tizoxanide (TZ) are being studied as a potential treatment for ACLF. Research has shown that NTZ may help reduce inflammation, prevent cell damage, and support organ function. Additionally, NTZ has broad anti-infectious properties against bacteria, viruses and parasites commonly found in the human gut. Since an imbalance in gut bacteria plays a role in ACLF, NTZ could help restore this balance by reducing bacterial overgrowth and gut dysbiosis, potentially protecting the intestinal barrier and improving overall health.